Summary of Insmed (INSM) Q2 2026 Earnings Call

1Key Financial Results and Metrics

BRINSUPRI Revenue: $309.2 million for Q2 2026, up 49% sequentially, exceeding expectations.

ARIKAYCE Revenue: $116.3 million, representing 8% growth year-over-year.

Gross to Net (GTN): Improved for BRINSUPRI to mid- to high 20s, with ARIKAYCE maintaining low to mid-20s.

Cost of Product Revenues: $67.2 million (16% of revenues), down from 26% in the prior year.

Cash Position: Approximately $1.2 billion, with a lower burn rate attributed to higher revenue generation.

Full Year Guidance for BRINSUPRI: Raised to $1.25 billion - $1.4 billion from over $1 billion.

ARIKAYCE Guidance: Reiterated at $450 million - $470 million.

2Strategic Updates and Business Highlights

BRINSUPRI Launch: Described as historic, with over 7,000 new patient starts in Q2, exceeding expectations. The drug is on track to become a leading treatment in specialty respiratory medicine.

ARIKAYCE Expansion: Progressing towards a potential label expansion to include all MAC lung disease in the U.S. and Japan.

TPIP Development: Positive results from ongoing studies, with potential applications across multiple indications (PH-ILD, PAH, PPF, IPF).

Leadership Addition: Samuele Butera appointed as Senior VP and GM of Global Respiratory Therapeutics, enhancing commercial capabilities.

Pipeline Development: IND clearance for INS1033, targeting rheumatoid arthritis, with plans for further clinical programs.

3Forward Guidance and Outlook

Peak Sales Estimates: Increased for BRINSUPRI to over $7 billion (up from $5 billion) and for TPIP to over $6 billion (up from $2 billion). Combined peak sales for the top three assets now exceed $14 billion.

Cash Flow Positivity: Expected in 2027, with sufficient resources to fund operations without raising additional capital until then.

Market Expansion: Focus on improving diagnosis among patients with comorbid conditions to increase the addressable market for BRINSUPRI.

4Bad News, Challenges, or Points of Concern

Regulatory Risks: Potential challenges in expanding BRINSUPRI's market internationally, particularly in Europe due to budget constraints and market access issues.

Competition: The introduction of a strong DPP1 competitor could impact market dynamics and sales projections.

Market Conditions: The ongoing uncertainty surrounding pricing negotiations in Japan and the impact of the IRA on future pricing strategies.

5Notable Q&A Insights

Patient Persistence: Metrics for refill behavior and adherence are tracking ahead of internal benchmarks, indicating strong demand and stability in patient retention.

New Patient Starts: All 7,000 new patient starts in Q2 were organic, with no "ready and waiting" patients remaining.

Prescribing Depth: 30% of prescribers are now writing for at least 5 patients, with expectations for this to increase as physicians gain confidence in BRINSUPRI.

TPIP's Competitive Position: Confidence in TPIP's ability to compete effectively in the market, particularly in IPF, was emphasized, with expectations of overcoming orphan designation challenges. Overall, Insmed reported a strong quarter with significant revenue growth and positive developments across its product portfolio, while also addressing potential challenges and competitive pressures in the market.